Pharmexa epitope deal with Epimmune

Pharmexa (CSE:PHARMX) received a non-exclusive license to EPMN's PADRE, a T cell epitope to enhance the immune system's response against antigens. PHARMX will use PADRE in conjunction with its AutoVac...